Austrian pharmaceutical research company specializing in neuroinflammation, chronic pain pharmacology, and natural product-derived therapeutics.
Bionorica Research GmbH is the Austrian research arm of the Bionorica group, a company with deep roots in plant-derived pharmaceutical products. Their H2020 work spans two complementary directions: natural product discovery from Mediterranean and global food plants for healthy ageing applications, and mechanistic pharmacology targeting neuroinflammation in chronic pain and neurodegenerative conditions. In their pain research, they work specifically with CB2 and CX3CR1 receptor pathways and investigate the role of cytokines, chemokines, and non-neuronal cells in pathological pain states. They function as an industry-anchored R&D partner in academic-led consortia, bridging phytochemical expertise with precision receptor pharmacology.
TOBeATPAIN (2018–2022) targeted CB2 and CX3CR1 receptors, cytokines, and non-neuronal cells to combat pathological pain in neurodegenerative diseases and painful peripheral neuropathies.
MediHealth (2016–2019) investigated natural compounds from Mediterranean diet and global food plants for healthy ageing applications.
TOBeATPAIN's keyword profile includes CB2 and CX3CR1 receptors as specific molecular targets for anti-neuroinflammatory intervention, indicating active work at the receptor biology level.
Their first H2020 project (MediHealth, 2016) reflects their pharmaceutical origins — broad natural product screening across Mediterranean and global food plants, with no recorded molecular-level keywords. By 2018, TOBeATPAIN shows a sharp pivot toward mechanistic pain research with highly specific molecular targets: CB2 receptors, CX3CR1, cytokines, chemokines, and non-neuronal cell biology in the context of peripheral neuropathies and neurodegeneration. The direction of travel is from broad phytochemical discovery toward precision neuropharmacology.
Bionorica Research is moving deeper into the neuropharmacology of pain and neurodegeneration, suggesting future collaborations will center on receptor biology, neuroinflammation, and therapeutic development for chronic pain and neurodegenerative conditions rather than broad natural product screening.
Bionorica Research has participated exclusively as a non-coordinating partner across both projects, indicating they contribute specialist pharmaceutical expertise rather than manage consortium operations. Both projects sit within MSCA schemes — one RISE (researcher exchange) and one ITN (training network) — which typically involve wide, multi-institutional networks across academia and industry. This profile marks them as a valued industry collaborator that academic consortia recruit for their R&D infrastructure and product development knowledge, not for project leadership.
Across just two projects, Bionorica Research built connections with 19 unique partners across 12 countries — a notably broad reach for an organization with so few projects. The MSCA-RISE scheme in particular drives wide international collaboration, likely extending their network beyond the EU.
As the research subsidiary of a company with established plant-based pharmaceutical products, Bionorica Research brings an unusual combination of industrial R&D capacity and phytochemical compound libraries to academic consortia — a combination most purely academic partners cannot replicate. Their pivot toward CB2/CX3CR1-targeted pain research positions them at the intersection of natural compound discovery and precision neuroinflammation pharmacology, a niche relevant to the fast-growing chronic pain therapeutics market. For consortium builders in pain, neuroscience, or plant medicine, they represent an industry anchor with credible product development history.
